Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy: The Swiss HIV Cohort Study

AIDS

Volumn 15, Issue 14, 2001, Pages 1793-1800

  Friedl, Andrée C ^a   Ledergerber, Bruno ^a   Flepp, Markus ^a   Hirschel, Bernard ^b   Telenti, Amalio ^c   Furrer, Hansjakob ^d   Bucher, Heiner C ^e   Bernasconi, Enos ^f   Weber, Rainer ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e KANTONSSPITAL BASEL   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Adult cohort study; AIDS; Antiretroviral therapy; Efavirenz; HIV; Protease inhibitors

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035964681     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109280-00008     Document Type: Article

References (19)

1. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
2. AIDS-Related opportunistic illness and potent antiretroviral therapy
3. Immunological effects of antiretroviral therapy
4. Factors affecting adherence to antiretroviral therapy
5. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens
6. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
7. Virological and clinical outcome of NNRTI-containing regimens for 1932 patients in EuroSIDA
8. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
9. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
10. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
11. Choosing the best initial therapy for HIV-1 infection
12. Clinical epidemiology and research on HIV infection in Switzerland: The Swiss HIV Cohort Study 1988-2000
13. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study
14. Partial residuals for the proportional hazards regression model
15. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
16. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials
17. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
18. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
19. Adherence to triple therapy and viral load response